Please login to the form below
osteoporosis
This page shows the latest osteoporosis news and features for those working in and with pharma, biotech and healthcare.
WHO and ESCEO partner to develop roadmap for bone health and ageing
osteoporosis are on the rise, posing an increasing and costly burden on healthcare systems. ... In this sense, the collaboration is truly a game-changer for people with osteoporosis worldwide.”.
Latest news
-
Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis
The application comprises all indications covered by Amgen’s reference medicines, Prolia and Xgeva, including osteoporosis in postmenopausal women and in men at an increased risk of fractures. ... Sandoz’s US application includes data from its phase 1
-
Amgen and UCB’s Evenity recommended by NICE for severe osteoporosis
In the UK, almost four million people are affected by osteoporosis, resulting in around 520, 000 fragility fractures each year. ... Postmenopausal women are disproportionately impacted by the condition and have a 50% chance of experiencing an osteoporosis
-
bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
Side effects from this treatment can cause complications such as organ damage, osteoporosis and problems with the heart, liver and endocrine system resulting in reduced life expectancy.
-
UCB/Amgen’s Evenity finally cleared for osteoporosis in Europe
UCB and Amgen have finally claimed European approval for their osteoporosis drug Evenity, which becomes the first new drug for the disease in the EU since 2010. ... showed impressive activity in reducing fracture rates and improving bone mineral density
-
Amgen exits neuroscience R&D to focus on growth areas
There was however an impressive $173m coming from Amgen’s own biosimilars business, up from $82m in the second quarter, with other gains for osteoporosis therapy Prolia (denosumab) – up 18% to
More from news
Approximately 13 fully matching, plus 194 partially matching documents found.
Latest Intelligence
-
Envisioning a healthier every day, for every woman
certain patients with breast cancer and certain patients with osteoporosis with high risk of fracture.
-
A new era for UK-Japanese scientific research relations
Japan’s health system is seeing a corresponding rise in the conditions common to an ageing population, such as cardiac disease, autoimmune diseases, diabetes, osteoporosis and osteoarthritis.
-
On our best behaviour
Poor adherence for example can completely undermine the value of medication – one study showed that poor adherence with osteoporosis medications results in around a 50% reduction in the potential benefits observed
-
The evolution of marketing – the Amgen way
There is tremendous opportunity – and a massive need – to bend the curve for serious illnesses, such as cancer, cardiovascular disease and osteoporosis, which affect tens of millions of people worldwide.
-
Case study: frACTure
The campaign featured on- and off-line communications and activities that educated employees about osteoporosis and fractures. ... It showed how committed the company is to raising awareness of osteoporosis and fragility fractures.
More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.
Latest appointments
-
Teva appoints Lilly directors to CEO positions in Asia
Hong has served as CEO of Lilly Korea since 2007. This followed four years as global marketing manager of an osteoporosis medication at Lilly's headquarters in the US.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
The power of influence in transforming women’s health
The clinical symptoms were identified as ‘hormone deficiency syndrome’[i] whose consequences included other chronic health conditions such as osteoporosis. ... In 1988, the US FDA approved HRT for the prevention of osteoporosis not just for the
-
Osteoblast Hackathon
Bringing together the disease community to hack ideas using design thinking as our foundation. 44 (0) 7817 410079. Address:. Second Home, 68 Hanbury Street. Shoreditch. E1 5JL. United Kingdom.
-
Cuttsy+Cuttsy launch their latest patient e-book
Osteoporosis is a chronic condition that affects up to one in three people aged 50 and over. ... If you or someone you know has osteoporosis, this book might help take some of the unknown away.
-
How can pharma engage with key stakeholders on NHS service transformation?
NHS RightCare provides examples of this with its long-term condition scenarios, such as ‘Susan’s Story: Osteoporosis’, where costs are shown to be reduced by a factor of 10 if
-
Maximising ROI from mature brands
News that Eli Lilly and Co has forecast a drop in 2014 profits and reduced its sales outlook because of generic competition to its Cymbalta antidepressant and Evista drug for osteoporosis,
More from PMHub
Approximately 2 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn
- Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
- UK-India research project trialling easy-to-use UTI test to support fight against AMR
- Cancer Research UK and Guardant collaborate to advance cancer detection and treatment
- Give the gift of positive change
- Apple Vision Pro: challenges and opportunities for pharma
No results were found
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
